Loss of gastric gland mucin-specific O-glycan is associated with progression of differentiated-type adenocarcinoma of the stomach.
Bottom Line: Loss of αGlcNAc was also significantly associated with poorer patient prognosis in MUC6-positive differentiated-type adenocarcinoma.In undifferentiated-type adenocarcinoma, we observed no significant correlation between mucin phenotypic marker expression, including MUC6, and any clinicopathologic variable.These results together indicate that loss of αGlcNAc in MUC6-positive cancer cells is associated with progression and poor prognosis in differentiated, but not undifferentiated, types of gastric adenocarcinoma.
Affiliation: Department of Molecular Pathology, Shinshu University Graduate School of Medicine, Matsumoto, Japan; Department of Gastroenterology, Aizawa Hospital, Matsumoto, Japan.Show MeSH
Related in: MedlinePlus
Mentions: Of samples from 54 patients with differentiated-type gastric adenocarcinoma showing MUC6-positivity in tumor cells, 33 (61.1%) lacked αGlcNAc expression (Table3). Notably, αGlcNAc expression was inversely correlated with depth of invasion, stage, and venous invasion. More importantly, analysis of 5-year cancer-specific survival rates of patients with MUC6-positive cancer cells revealed that individuals with αGlcNAc-negative tumors had a significantly poorer outcome than those showing αGlcNAc-positive tumors (P = 0.048) (Fig.5a).
Affiliation: Department of Molecular Pathology, Shinshu University Graduate School of Medicine, Matsumoto, Japan; Department of Gastroenterology, Aizawa Hospital, Matsumoto, Japan.